{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 27,
  "pageCount": 366,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "villain_critique",
  "function": "name_villain",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a comparative analysis of pricing and regulatory status to undermine the competitor's market position.",
  "elementsJson": [
    "paragraph",
    "screenshot"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/27",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-27",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Comically, even the clinical trials show Wakix is inferior to modafinil, which leaves only one conceivable argument: that it is easier to prescribe because it’s not a controlled substance, the flimsy thread by which its FDA approval, commercial pitch, and stock narrative hangs.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cca-623d880ba019",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.54,
        "x": 0.39,
        "y": 0.58
      },
      "kind": "image",
      "text": "Wakix non-controlled substance marketing claim",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f4140c6-3a10-4849-932a-89185d8b985f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.29,
        "x": 0.07,
        "y": 0.58
      },
      "kind": "image",
      "text": "Amazon Pharmacy Modafinil listing",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d010badd-e08d-402c-8ea2-29b3e0eb0014",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "Harmony's dilemma is obvious – in a crowded field, what's the value proposition, particularly at ~$175,000/year? It is not a cure for narcolepsy, and of the two symptoms it is approved for, cataplexy is ultra-rare, not serious, and easily treated. That leaves EDS – excessive daytime sleepiness – which unfortunately has countless treatments. The standard of care and first-line treatment is typically modafinil, a CNS stimulant available as a generic for $10-15/month or under brand names like Provigil, or its longer-acting variant armodafinil (Nuvigil, FDA approved for EDS in narcolepsy). Doctors then step-through and/or combine anti-depressants, stimulants, and sodium oxybate. Comically, even the clinical trials show Wakix is inferior to modafinil, which leaves only one conceivable argument: that it is easier to prescribe because it's not a controlled substance, the flimsy thread by which its FDA approval, commercial pitch, and stock narrative hangs.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4890094e-ddc7-4f7f-8268-42b6b9e25975",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "WAKIX is the first and only FDA-approved treatment for people with narcolepsy that is not a controlled substance. — Wakix.com",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cca-65a61c420b5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.07,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: https://wakix.com/",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dad5096f-2776-48d9-960c-aa0bb5853e67",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "antagonist-introduction",
      "slug": null,
      "matchId": "307fd782-8efe-4c79-89ac-9633c997112f",
      "evidence": "The slide frames Harmony/Wakix as the 'villain' with a 'flimsy' value proposition.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 30,
      "from": 11,
      "beatId": "d0905c6f-1d0c-46ed-96fd-5548f20fae57",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Monster",
      "beatSlug": null,
      "evidence": "The document presents the 'monster' of the company's troubled drug and financial reporting",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 20,
      "name": "Aha Moment",
      "slug": "03-aha-moment",
      "bestFor": "Data-heavy sections, research findings, analytical arguments",
      "matchId": "b545ff30-50fa-4d68-abe5-bb3c4c439c61",
      "evidence": "The document presents a series of testimonials and data that build a case against the company",
      "position": 0,
      "objective": "To reveal the truth about the company's troubled drug and financial reporting",
      "structure": "The Problem/Question -> What the Data Shows -> The Insight",
      "confidence": 0.8,
      "description": "Establish a tension, present data, then deliver the insight that changes everything"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}